Shubh K Patel, Miriam S Badross, Nitish K Dhingra, Michael Moroney, Jack H Casey, Syed M Ali Hassan, Tayyab S Khan, David A Hess, Marlys L Koschinsky, Hwee Teoh, Subodh Verma
{"title":"Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery: A Narrative Review.","authors":"Shubh K Patel, Miriam S Badross, Nitish K Dhingra, Michael Moroney, Jack H Casey, Syed M Ali Hassan, Tayyab S Khan, David A Hess, Marlys L Koschinsky, Hwee Teoh, Subodh Verma","doi":"10.1016/j.athoracsur.2025.01.013","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coronary artery bypass grafting (CABG) remains a cornerstone in the management of coronary artery disease (CAD). In non-urgent surgical revascularization cases, preoperative optimization of modifiable risk factors can improve outcomes. There is increasing interest in the relationship between lipoprotein(a) levels and the risk for ischemic cardiovascular disease, particularly how CABG outcomes are in turn affected. This review highlights the role of Lp(a) in the pathogenesis of CAD and CABG outcomes and discusses future directions for its optimal management in the perioperative period.</p><p><strong>Methods: </strong>A review of the PubMed/MEDLINE database until March 2024 was performed to capture publications that evaluated and/or described the relationship between lipoprotein(a) and CABG surgery or CAD outcomes.</p><p><strong>Results: </strong>The available literature supports lipoprotein(a) as a causal and independent risk factor for the pathogenesis of CAD. Elevated lipoprotein(a) levels are associated with an increased risk of adverse post-CABG outcomes, including graft occlusion incidence and major adverse cardiovascular events. Genetic variations influencing lipoprotein(a) levels play a role in disease progression and surgical outcomes. Several therapies aimed at reducing lipoprotein(a) levels, currently in phase III clinical trials, show promise for improving post-CABG prognosis.</p><p><strong>Conclusions: </strong>Among individuals undergoing surgical revascularization for CAD, lipoprotein(a) levels may help define risk and inform best practices for perioperative management. We advocate for the routine measurement of lipoprotein(a) in all patients undergoing CABG. Emerging lipoprotein(a)-lowering agents show promise for secondary prevention of cardiac events, though dedicated analyses in cardiac surgical sub-cohorts will be important to evaluate their role in improving CABG outcomes.</p>","PeriodicalId":50976,"journal":{"name":"Annals of Thoracic Surgery","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Thoracic Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.athoracsur.2025.01.013","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Coronary artery bypass grafting (CABG) remains a cornerstone in the management of coronary artery disease (CAD). In non-urgent surgical revascularization cases, preoperative optimization of modifiable risk factors can improve outcomes. There is increasing interest in the relationship between lipoprotein(a) levels and the risk for ischemic cardiovascular disease, particularly how CABG outcomes are in turn affected. This review highlights the role of Lp(a) in the pathogenesis of CAD and CABG outcomes and discusses future directions for its optimal management in the perioperative period.
Methods: A review of the PubMed/MEDLINE database until March 2024 was performed to capture publications that evaluated and/or described the relationship between lipoprotein(a) and CABG surgery or CAD outcomes.
Results: The available literature supports lipoprotein(a) as a causal and independent risk factor for the pathogenesis of CAD. Elevated lipoprotein(a) levels are associated with an increased risk of adverse post-CABG outcomes, including graft occlusion incidence and major adverse cardiovascular events. Genetic variations influencing lipoprotein(a) levels play a role in disease progression and surgical outcomes. Several therapies aimed at reducing lipoprotein(a) levels, currently in phase III clinical trials, show promise for improving post-CABG prognosis.
Conclusions: Among individuals undergoing surgical revascularization for CAD, lipoprotein(a) levels may help define risk and inform best practices for perioperative management. We advocate for the routine measurement of lipoprotein(a) in all patients undergoing CABG. Emerging lipoprotein(a)-lowering agents show promise for secondary prevention of cardiac events, though dedicated analyses in cardiac surgical sub-cohorts will be important to evaluate their role in improving CABG outcomes.
期刊介绍：
The mission of The Annals of Thoracic Surgery is to promote scholarship in cardiothoracic surgery patient care, clinical practice, research, education, and policy. As the official journal of two of the largest American associations in its specialty, this leading monthly enjoys outstanding editorial leadership and maintains rigorous selection standards.
The Annals of Thoracic Surgery features:
• Full-length original articles on clinical advances, current surgical methods, and controversial topics and techniques
• New Technology articles
• Case reports
• "How-to-do-it" features
• Reviews of current literature
• Supplements on symposia
• Commentary pieces and correspondence
• CME
• Online-only case reports, "how-to-do-its", and images in cardiothoracic surgery.
An authoritative, clinically oriented, comprehensive resource, The Annals of Thoracic Surgery is committed to providing a place for all thoracic surgeons to relate experiences which will help improve patient care.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
